Get the latest Science News and Discoveries

An intranasal formulation of psychedelic 5-MeO-DMT (BPL-003) has completed a Phase 1 study of safety, tolerability and pharmacokinetics. BPL-003's effects were felt within minutes and resolved within 90 minutes. Drug now progressing into trial of people with treatment-resistant depression.

None

Related news:

The X-37B is Back After 908 Days in Orbit. What was it Doing up There? That's Classified

Smoking Cannabis Could Harm Your Lungs More Than Tobacco, Study Finds

Study compares adverse events after two types of bariatric surgery in adolescents